lymphoma

By Targets:	Anaplastic lymphoma kinase (ALK) (14) BCL6 (3) MALT1 (8) ADC Antibody (2) ADC Cytotoxin (6) Adenosine Deaminase (1) Akt (3) Antibiotic (5) Antibody-Drug Conjugates (ADCs) (3) Antifolate (2) Apoptosis (61) Arp2/3 Complex (1) ATM/ATR (2) Aurora Kinase (1) Autophagy (8) Bacterial (4) Bcl-2 Family (18) Bcr-Abl (1) Btk (16) c-Myc (2) Casein Kinase (4) Caspase (4) CCR (1) CD19 (2) CD20 (6) CD22 (4) CD28 (1) CD3 (1) CDK (7) COX (2) CRM1 (1) CXCR (2) Cytochrome P450 (2) Deubiquitinase (1) Dihydroorotate Dehydrogenase (1) DNA Alkylator/Crosslinker (5) DNA Methyltransferase (1) DNA/RNA Synthesis (7) Drug Metabolite (1) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (11) E3 Ligase Ligand-Linker Conjugates (2) EGFR (4) Endogenous Metabolite (2) FAK (1) FLT3 (4) Free Fatty Acid Receptor (1) Fungal (4) Glutaminase (1) HDAC (8) Histone Acetyltransferase (1) Histone Methyltransferase (16) HIV (4) HSV (1) IAP (1) IGF-1R (1) IKK (1) Influenza Virus (2) Integrin (2) Interleukin Related (2) IRAK (14) Isotope-Labeled Compounds (2) Itk (1) JAK (2) JNK (1) Lactate Dehydrogenase (1) Ligands for E3 Ligase (5) Ligands for Target Protein for PROTAC (2) Liposome (1) MAP3K (1) MDM-2/p53 (5) MetAP (1) Methionine Adenosyltransferase (MAT) (1) MicroRNA (1) Microtubule/Tubulin (7) Mitochondrial Metabolism (2) MMP (1) Molecular Glues (7) NAMPT (1) Necroptosis (1) NF-κB (2) Notch (2) Nucleoside Antimetabolite/Analog (2) P-glycoprotein (1) Parasite (3) PARP (1) PD-1/PD-L1 (7) Phosphatase (2) PI3K (9) Pim (1) PROTACs (10) Proteasome (2) Pyroptosis (1) RAR/RXR (2) Ras (3) Reactive Oxygen Species (3) ROS Kinase (1) SARS-CoV (1) Ser/Thr Protease (1) SHMT (1) SphK (1) Src (2) STAT (3) Survivin (2) TNF Receptor (6) Topoisomerase (6) Trk Receptor (1) VEGFR (2) Wnt (2) β-catenin (4)
By Research Areas:	Cancer (264) Cardiovascular Disease (2) Endocrinology (2) Infection (19) Inflammation/Immunology (45) Metabolic Disease (1) Neurological Disease (6)
Click Chemistry:	Alkynes (2)

Targets Recommended: Anaplastic lymphoma kinase (ALK) MALT1 BCL6

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147090

Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH	Histone Methyltransferase	Cancer
Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH (Compound 21b) is an EZH2 degrader and can be used for the research of lymphoma .

HY-14171S

Bexarotene-d4 LGD1069 d₄	RAR/RXR Autophagy	Cancer
Bexarotene-d₄ is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].

HY-131246

DM-01	Histone Methyltransferase	Cancer
DM-01 is a powerful and selective EZH2 inhibitor for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors .

HY-147091

Tazemetostat de(methyl morpholine)-COOH	Ligands for Target Protein for PROTAC	Cancer
Tazemetostat de(methyl morpholine)-COOH (compound 7) is a ligand for the PROTAC target protein EZH2, which can be used to synthesis of EZH2 degraders (PROTACs). EZH2 degraders have potent cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphoma .

HY-160520

ALK-IN-28

Anaplastic lymphoma kinase (ALK) Cancer

ALK-IN-28 (compound 22) is an inhibitor of anaplastic lymphoma kinase (ALK) .

ALK-IN-28	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-28 (compound 22) is an inhibitor of anaplastic lymphoma kinase (ALK) .

HY-160698

SGR-1505	MALT1	Cancer
SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proliferative activity in BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 can be used for research of B-cell lymphomas .

HY-109029

Dezapelisib INCB040093	PI3K	Cancer
Dezapelisib (NCB040093) is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ). Dezapelisib is a promising research strategy for select R/R B-cell lymphomas .

HY-109108

Valemetostat 1 Publications Verification DS-3201	Histone Methyltransferase	Cancer
Valemetostat (DS-3201), a first-in-class EZH1/2 dual inhibitor with IC₅₀ values ＜10 nM. Valemetostat can be used for the research of relapsed/refractory peripheral T-cell lymphoma .

HY-P99483

Blontuvetmab

AT 004; VT 007
CD20 Cancer

Blontuvetmab (AT 004)is a caninized CD20 monoclonal antibody. Blontuvetmab can be used for the research of Canine B-cell lymphoma .

Blontuvetmab AT 004; VT 007	CD20	Cancer
Blontuvetmab (AT 004)is a caninized CD20 monoclonal antibody. Blontuvetmab can be used for the research of Canine B-cell lymphoma .

HY-P99056

Utomilumab PF 05082566	TNF Receptor	Inflammation/Immunology Cancer
Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20 ⁺ non-Hodgkin lymphomas (NHL) .

HY-P99501

Zuberitamab

HS006
CD20 Cancer

Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .

Zuberitamab HS006	CD20	Cancer
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .

HY-19990

ALK kinase inhibitor-1	Anaplastic lymphoma kinase (ALK)	Cancer
ALK kinase inhibitor-1 is an *anaplastic lymphoma* kinase (ALK)** inhibitor extracted from patent US20130261106A1 compound I-202 .

HY-150019

PI3K-IN-36

PI3K Cancer

PI3K-IN-36 (compound A36) is a potent PI3K inhibitor. PI3K-IN-36 can be used in research of follicular lymphoma (FL) .

PI3K-IN-36	PI3K	Cancer
PI3K-IN-36 (compound A36) is a potent PI3K inhibitor. PI3K-IN-36 can be used in research of follicular lymphoma (FL) .

HY-P1258

PSI Proteasome Inhibitor 1; Z-Ile-Glu(OtBu)-Ala-Leu-CHO	Proteasome	Infection Cancer
PSI (Proteasome Inhibitor 1) is a potent proteasome inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

HY-P1258A

PSI TFA Proteasome Inhibitor 1 TFA; Z-Ile-Glu(OtBu)-Ala-Leu-CHO TFA	Proteasome	Infection Cancer
PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

HY-P99619

Finotonlimab SCT-I10A	PD-1/PD-L1	Cancer
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .

HY-151395

Tubulin polymerization-IN-34	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-34 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, demonstrates high selectivity against marginal zone lymphoma VL51 cell line .

HY-151396

Tubulin polymerization-IN-35	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-35 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, demonstrates high selectivity against marginal zone lymphoma VL51 cell line .

HY-P99289

Epratuzumab Antibody hLL 2; Anti-Human CD22 Recombinant Antibody	CD22	Inflammation/Immunology Cancer
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .

HY-148026

Sonrotoclax BGB 11417	Bcl-2 Family	Cancer
Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines .

HY-P99952

Ripertamab SCT400	CD20	Cancer
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .

HY-P99253

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-P99293

Galiximab IDEC 114; Anti-Human CD80 Recombinant Antibody	CD28	Cancer
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .

HY-129226

SHMT-IN-2	SHMT	Endocrinology Cancer
SHMT-IN-2 is a stereo specific inhibitor of human SHMT1/2 with IC₅₀ values of 13 nM and 66 nM for SHMT1 and SHMT2, respectively. SHMT-IN-2 can block the growth of many human cancer cells, and has sensitivity for B-cell lymphomas .

HY-151393

Tubulin polymerization-IN-32	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-32 is a tubulin polymerization inhibitor. Tubulin polymerization-IN-32 inhibits cancer cell proliferation. Tubulin polymerization-IN-32 can be used in the research of cancers like lymphomas .

HY-120231

Z-VRPR-FMK	MALT1	Cancer
Z-VRPR-FMK is an irreversible MALT1 protein inhibitor. Z-VRPR-FMK inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression .

HY-149221

Apoptosis inducer 11	Apoptosis	Cancer
Apoptosis inducer 11 (compound 3u) induces apoptosis through the mitochondrial pathway. Apoptosis inducer 11 induces a block in G2/M, a strong decrease in S phase in non-Hodgkin lymphoma cell lines .

HY-123950

MMRi64	MDM-2/p53 Apoptosis	Cancer
MMRi64 disrupts Mdm2-MdmX interactions. MMRi64 downregulates Mdm2 and MdmX in leukemia cells. MMRi64 induces p53 accumulation, and induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. MMRi64 can be used for cancer research .

HY-155557

Anti-inflammatory agent 45	Apoptosis	Cancer
Anti-inflammatory agent 45 (compound 2v) is an anticancer agent with direct inhibitory effects on the growth of different blood cancers including leukemia, lymphoma and myeloma cell lines. Anti-inflammatory agent 45 induces apoptosis and inhibits NO production in HL60 leukemia cells (IC₅₀=14.7 μM) .

HY-156553

BTK-IN-27	Btk	Inflammation/Immunology Cancer
BTK-IN-27 (example 8) is a BTK inhibitor (IC₅₀: 0.2 nM). BTK-IN-27 shows anti-proliferative activity in TMD8 cells (IC₅₀: < 5 nM). BTK-IN-27 can be used for research of cancer, lymphoma, leukemia and immunological diseases .

HY-146183

BCL6-IN-9	Bcl-2 Family	Cancer
BCL6-IN-9 (compound 1) is a potent *B-cell lymphoma* 6 protein (BCL6) inhibitor, with an IC₅₀** of 3.9 nM. BCL6-IN-9 can be used for the research of cancer .

HY-P99107

Brentuximab vedotin	Antibody-Drug Conjugates (ADCs) Apoptosis TNF Receptor	Cancer
Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC₅₀ of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma .

HY-153320

AZ-TAK1

MAP3K Cancer

AZ-TAK1, an ATP-competitive small molecule inhibitor of TAK1, dephosphorylates TAK1, p38, and IκB-α in lymphoma cell lines .

AZ-TAK1	MAP3K	Cancer
AZ-TAK1, an ATP-competitive small molecule inhibitor of TAK1, dephosphorylates TAK1, p38, and IκB-α in lymphoma cell lines .

HY-155225

BTM-3566	Mitochondrial Metabolism Apoptosis	Cancer
BTM-3566 is an OMA1 activator. BTM-3566 activates the mitochondrial stress response. BTM-3566 induces apoptosis in diffuse large B-cell lymphomas (DLBCL) cell lines .

HY-44432

Navitoclax-piperazine ABT-263-piperazine	Bcl-2 Family Ligands for Target Protein for PROTAC	Cancer
Navitoclax-piperazine (ABT-263-piperazine) is a *B-cell lymphoma* extra large (BCL-XL)** inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604) .

HY-132253

Polatuzumab vedotin	Antibody-Drug Conjugates (ADCs)	Cancer
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-141432

NX-1607 Cbl-b-IN-3	E1/E2/E3 Enzyme	Cancer
Cbl-b-IN-3 (Compound 23) is a casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) inhibitor with an IC₅₀ of < 1 nM. Cbl-b is an E3 ubiquitin ligase that negatively regulates T-cell activation .

HY-N12122

Dehydropipernonaline	Fungal	Neurological Disease
Dehydropipernonaline (Compound 24) is an amide compound. Dehydropipernonaline shows considerable cytotoxicity to L5178Y mouse lymphoma cells (IC₅₀8.9μM). Dehydropipernonaline can be used for screening antifungal and cytotoxicity .

HY-145261

hDHODH-IN-8	Dihydroorotate Dehydrogenase	Inflammation/Immunology
hDHODH-IN-8 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC₅₀ of 16 nM. hDHODH-IN-8 has potent antiproliferative activity and excellent aqueous solubility. hDHODH-IN-8 has the potential for the research of tumor disease, especially lymphoma .

HY-146237

Golcadomide CC-99282	Ligands for E3 Ligase Molecular Glues	Cancer
Golcadomide (CC-99282) is a potent and orally active cereblon (CRBN) E3 ligase modulator (CELMoD). Golcadomide co-opts CRBN to induce potent and targeted degradation of Ikaros and Aiolos. Golcadomide can be used for researching non-Hodgkin lymphomas .

HY-151397

Tubulin polymerization-IN-36	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-36 is a tubulin polymerization inhibitor (IC₅₀: 2.8 μΜ). Tubulin polymerization-IN-36 binds to the colchicine site of tubulin and inhibits colchicine binding. Tubulin polymerization-IN-36 can be used in the research of cancers, such as lymphomas .

HY-151398

Tubulin polymerization-IN-37	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-37 is a tubulin polymerization inhibitor (IC₅₀: 2.3 μΜ). Tubulin polymerization-IN-37 binds to the colchicine site of tubulin and inhibits colchicine binding. Tubulin polymerization-IN-37 can be used in the research of cancers, such as lymphomas .

HY-144288

BLK-IN-2	Btk	Cancer
BLK-IN-2 (compound 25) is a potent and selective irreversible inhibitor of B-Lymphoid tyrosine kinase (BLK), with an IC₅₀ of 5.9 nM. BLK-IN-2 also inhibits BTK (IC₅₀=202.0 nM). BLK-IN-2 shows potent antiproliferative activities against several lymphoma cells .

HY-147741

DPPY	JAK Btk EGFR	Inflammation/Immunology Cancer
DPPY (compound 6) is a potent PTK inhibitor with IC₅₀ values of <10, <10, <10 nM for EGFR, BTK, JAK3, respectively. DPPY shows anti-proliferative activity against B-cell lymphoma cells. DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF) .

HY-148281

TMX-2164	Bcl-2 Family	Cancer
TMX-2164 is a potent, irreversible *B-cell lymphoma* 6 (BCL6) inhibitor with an IC₅₀** value of 152 nM. TMX-2164 displays sustained target engagement and antiproliferative activity in cells .

HY-150594

IRAK4-IN-17

IRAK NF-κB Cancer

IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC₅₀ of 1.3 nM . IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research .

IRAK4-IN-17	IRAK NF-κB	Cancer
IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC₅₀ of 1.3 nM . IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research .

HY-134039

5-Hydroxy-8-methoxypsoralen 5-Hydroxyxanthotoxin	Others	Inflammation/Immunology
5-Hydroxy-8-methoxypsoralen (5-Hydroxyxanthotoxin) is a metabolite of Xanthotoxin. Xanthotoxin is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight .

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .

HY-109109

Alteminostat CKD-581	HDAC Apoptosis	Cancer
Alteminostat (CKD-581) is a potent HDAC inhibitor. Alteminostat inhibits the class I-II HDAC family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research .

HY-32736

Triptonide 2 Publications Verification NSC 165677; PG 492	Wnt β-catenin Apoptosis Autophagy	Inflammation/Immunology Cancer
Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a Wnt signaling inhibitor with an IC₅₀ of appropriately 0.3 nM. Triptonide has immunosuppression, anti-inflammatory, anti-fertility, neuroprotective and anti-lymphoma effects .

Cat. No.	Product Name

HY-L171

Anti-Hematopathy Compound Library

2687 Compounds compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 2687 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

HY-L079

Anti-Blood Cancer Compound Library

2657 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2657 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L075

Anti-Lung Cancer Compound Library

1823 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 1823 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-16700G

PNU-159682 (GMP)	Fluorescent Dye
PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.

Cat. No.	Product Name	Type

HY-E70016

Terminal deoxyribonucleotidyltransferase TdT	Biochemical Assay Reagents
Terminal deoxyribonucleotidyltransferase (TdT) catalyses the condensation of deoxyribonucleotide triphosphates onto the 3' hydroxyl ends of DNA strands and adds N-regions to gene segment junctions during V(D)J recombination. Terminal deoxyribonucleotidyltransferase is expressed in immature, pre-B, pre-T lymphoid cells, and acute lymphoblastic leukemia/lymphoma cells .

HY-16700G

PNU-159682 (GMP)	Biochemical Assay Reagents
PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.

HY-151506

Phospholipid PL1	Drug Delivery
Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity .

Cat. No.	Product Name	Target	Research Area

HY-P1258

PSI Proteasome Inhibitor 1; Z-Ile-Glu(OtBu)-Ala-Leu-CHO	Proteasome	Infection Cancer
PSI (Proteasome Inhibitor 1) is a potent proteasome inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

HY-P1407

Z-VRPR-FMK TFA VRPR	MALT1 Influenza Virus	Infection Cancer
Z-VRPR-FMK (TFA) (VRPR), a tetrapeptide, is a selective and irreversible MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor. Z-VRPR-FMK (TFA) can protect against influenza A virus (IAV) infection .

HY-P1258A

PSI TFA Proteasome Inhibitor 1 TFA; Z-Ile-Glu(OtBu)-Ala-Leu-CHO TFA	Proteasome	Infection Cancer
PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

HY-100866B

F1324 acetate	Bcl-2 Family	Cancer
F1324 acetate is a potent, high affinity peptidic inhibitor of *B cell lymphoma* 6 (BCL6), with an IC₅₀** of 1 nM. F1324 acetate exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-100866A

F1324 TFA	Bcl-2 Family	Cancer
F1324 TFA is a potent, high affinity peptidic inhibitor of *B cell lymphoma* 6 (BCL6), with an IC₅₀** of 1 nM. F1324 TFA exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-P3602

C3 Peptide P16	Peptides	Cancer
C3 Peptide P16, is a 16 amino acid synthetic peptide derived from human C3d, a fragment generated in trypsin-cleaved C3. C3 Peptide P16 enhances in vitro phosphorylation of pp105 and pp100, a cellular component presenting in the human B lymphoma cells .

HY-P5472

Tumour-associated MUC1 epitope	Peptides	Others
Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)

Cat. No.	Product Name	Target	Research Area

HY-P99055

Urelumab	Inhibitory Antibodies	Inflammation/Immunology Cancer
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .

HY-P99483

Blontuvetmab

AT 004; VT 007
CD20 Cancer

Blontuvetmab (AT 004)is a caninized CD20 monoclonal antibody. Blontuvetmab can be used for the research of Canine B-cell lymphoma .

HY-P99056

Utomilumab PF 05082566	TNF Receptor	Inflammation/Immunology Cancer
Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20 ⁺ non-Hodgkin lymphomas (NHL) .

HY-P99851

Detumomab SPECIFID	Inhibitory Antibodies	Cancer
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).

HY-P99501

Zuberitamab

HS006
CD20 Cancer

Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .

HY-P99619

Finotonlimab SCT-I10A	PD-1/PD-L1	Cancer
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .

HY-P99289

Epratuzumab Antibody hLL 2; Anti-Human CD22 Recombinant Antibody	CD22	Inflammation/Immunology Cancer
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .

HY-P99952

Ripertamab SCT400	CD20	Cancer
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .

HY-P99253

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-P99293

Galiximab IDEC 114; Anti-Human CD80 Recombinant Antibody	CD28	Cancer
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .

HY-132253

Polatuzumab vedotin	Antibody-Drug Conjugates (ADCs)	Cancer
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-P99273

Vorsetuzumab Anti-Human CD70 Recombinant Antibody	Inhibitory Antibodies	Cancer
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma .

HY-P99369

Lacutamab IPH 4102; Anti-KIR3DL2/CD158k Reference Antibody (lacutamab)	Inhibitory Antibodies	Cancer
Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma .

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells .

HY-P99230

Pinatuzumab	Integrin CD22	Cancer
Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL) .

HY-P99224

Veltuzumab IMMU-106; hA20	Integrin	Cancer
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC₅₀ value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .

HY-P99266

Zanolimumab Anti-Human CD4 Recombinant Antibody	Inhibitory Antibodies	Inflammation/Immunology Cancer
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .

HY-P99922

Encelimab	Inhibitory Antibodies	Cancer
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .

HY-P99233

Camidanlumab HuMax-TAC	Interleukin Related	Cancer
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia .

HY-P99338

Tisagenlecleucel CTL019	CD19	Inflammation/Immunology Cancer
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .

HY-P99349

Loncastuximab tesirine Loncastuximab tesirine-lpyl; ADCT-402	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .

HY-P99656

Iladatuzumab MCDS0593A	ADC Antibody	Cancer
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .

HY-P99024

Glofitamab RO7082859	CD20	Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma .

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

HY-P99033

Mosunetuzumab BTCT-4465A	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P99711

Loncastuximab RB4v1.2	CD19	Cancer
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) .

HY-P99669

Iratumumab MDX-060	TNF Receptor	Cancer
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99464

Bectumomab IMMU-LL 2	CD22	Cancer
Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .

HY-P9910

Obinutuzumab GA101; Anti-Human CD20 type II, Humanized Antibody	CD20	Cancer
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

HY-P9971

Camrelizumab 1 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P99579

Tamtuvetmab AT-005; AT005	Inhibitory Antibodies	Cancer
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary .

HY-P99015

Dacetuzumab	TNF Receptor	Cancer
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .

HY-P99167

Lucatumumab HCD122	TNF Receptor	Cancer
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .

HY-P99533

Urabrelimab

SRF-231; SRF231
Interleukin Related Cancer

Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .

HY-P99272

Ulocuplumab BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

HY-P99175

KWAR 23	Inhibitory Antibodies	Cancer
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .

HY-P99108

Penpulimab

PD-1/PD-L1 Inflammation/Immunology Cancer

Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-P99215

Parsatuzumab Anti-EGFL7; RG 7414	VEGFR	Cancer
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-32736

Triptonide 2 Publications Verification NSC 165677; PG 492	Classification of Application Fields Terpenoids Source classification Celastraceae Diterpenoids Plants Tripterygium wilfordii Hook. f. Disease Research Fields Inflammation/Immunology	Wnt β-catenin Apoptosis Autophagy
Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a Wnt signaling inhibitor with an IC₅₀ of appropriately 0.3 nM. Triptonide has immunosuppression, anti-inflammatory, anti-fertility, neuroprotective and anti-lymphoma effects .

HY-N3062

Pinobanksin 3,5,7-Trihydroxyflavanone	Flavanonols Structural Classification Flavonoids Classification of Application Fields Pinaceae Source classification Other Diseases Phenols Polyphenols Plants Pinus morrisonicola Hayata Disease Research Fields	Apoptosis
Pinobanksin has apoptotic induction in a B-cell lymphoma cell line .

HY-N2622

Oxypeucedanin hydrate (+)-Oxypeucedanin hydrate	Classification of Application Fields Source classification Coumarins Phenylpropanoids Plants Umbelliferae Helogyne apaloidea Nutt. Disease Research Fields Cancer	Others
Oxypeucedanin hydrate ((+)-Oxypeucedanin hydrate) is a natural product isolated from D. anethifolia. Prangol exhibits mild toxicity on fibroblasts and parental lymphoma cells .

HY-N12122

Dehydropipernonaline	Structural Classification Alkaloids Piperidine Alkaloids Source classification Piperaceae Plants Piper retrofractum Vahl	Fungal
Dehydropipernonaline (Compound 24) is an amide compound. Dehydropipernonaline shows considerable cytotoxicity to L5178Y mouse lymphoma cells (IC₅₀8.9μM). Dehydropipernonaline can be used for screening antifungal and cytotoxicity .

HY-134039

5-Hydroxy-8-methoxypsoralen 5-Hydroxyxanthotoxin	Saussurea medusa Maxim. Monophenols Classification of Application Fields Source classification Coumarins Phenols Phenylpropanoids Plants Umbelliferae Disease Research Fields Inflammation/Immunology	Others
5-Hydroxy-8-methoxypsoralen (5-Hydroxyxanthotoxin) is a metabolite of Xanthotoxin. Xanthotoxin is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight .

HY-128553

Antineoplaston A10	Alkaloids Piperidine Alkaloids Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Ras Apoptosis Endogenous Metabolite
Antineoplaston A10, a naturally occurring substance in human body, is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer .

HY-30151

Methoxsalen 10+ Cited Publications 8-Methoxypsoralen; Xanthotoxin; 8-MOP	Structural Classification other families Classification of Application Fields Source classification Coumarins Phenylpropanoids Plants Disease Research Fields Cancer	Cytochrome P450
Methoxsalen (8-Methoxypsoralen) is a furanocoumarin compound used in psoralen, used in studies of psoriasis, eczema, vitiligo and some sun-exposed cutaneous lymphomas, and is a P450 inhibitor.

HY-N3001

Isolinderalactone	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Lauraceae Disease Research Fields Lindera aggregata (Sims) Kosterm. Cancer	VEGFR Bcl-2 Family Survivin IAP
Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through the inhibition of VEGFR2 activation in endothelial cells . Isolinderalactone suppresses the expression of *B-cell lymphoma* 2 (Bcl-2), survi**

HY-N12436

11α-O-Tigloyl-12β-O-acetyltenacigenin B	Structural Classification Natural Products Source classification Marsdenia tenacissima (Roxb.) Moon Asclepiadaceae Plants	Aurora Kinase
11α-O-Tigloyl-12β-O-acetyltenacigenin B is an ester derivative of Tenacigenin B (HY-N1168), which is isolated from Garcinia cambogia (MTC). Tenacigenin B modulates the antitumor effects of Aurora-A in lymphoma.

HY-13062

Daunorubicin hydrochloride Maximum Cited Publications 22 Publications Verification Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Anthraquinones Source classification Phenols Polyphenols Disease Research Fields	Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Bacterial Autophagy Apoptosis Antibiotic
Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .

HY-13062A

Daunorubicin Daunomycin; RP 13057; Rubidomycin	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Anthraquinones Source classification Phenols Polyphenols Disease Research Fields	Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Autophagy Bacterial Antibiotic Apoptosis
Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .

HY-N6652

1-beta-D-Arabinofuranosyluracil 1 Publications Verification Uracil 1-β-D-arabinofuranoside	Cardiovascular Disease Natural Products Classification of Application Fields Animals Source classification Inflammation/Immunology Disease Research Fields	Others
1-beta-D-Arabinofuranosyluracil (Uracil 1-β-D-arabinofuranoside) isolated from the Caribbean sponge Tectitethya crypta, is a methoxyadenosine derivative. 1-beta-D-Arabinofuranosyluracil has demonstrated a diverse bioactivity profile including anti-inflammatory activity, analgesic and vasodilation properties . 1-beta-D-Arabinofuranosyluracil reduces a proliferation of mouse lymphoma cells .

HY-N6703

ar-Turmerone (+)-ar-Turmerone	Natural Products Classification of Application Fields Source classification Plants Curcuma longa Disease Research Fields Inflammation/Immunology Zingiberaceae	Apoptosis
ar-Turmerone ((+)-ar-Turmerone) is a major bioactive compound of the herb Curcuma longa with anti-tumorigenesis and anti-inflammatory activities . ar-Turmerone activates apoptotic protein in human lymphoma U937 cells . ar-Turmerone exerts positive modulation on murine DCs. ar-Turmerone induces NSC proliferation and constitutes a promising therapeutic agent for various neurologic disorders .

HY-N4126

6-Demethoxytangeretin	Flavonoids other families Neurological Disease Classification of Application Fields Flavones Source classification Rutaceae Plants Inflammation/Immunology Disease Research Fields Citrus reticulata Blanco Cancer	Anaplastic lymphoma kinase (ALK)
6-Demethoxytangeretin is a citrus flavonoid isolated from Citrus reticulata. 6-Demethoxytangeretin exerts anti-inflammatory activity and anti-allergic activity, suppresses production and gene expression of interleukin-6 in human mast cell-1 via anaplastic lymphoma kinase (ALK) and mitogen-activated protein kinase (MAPK) pathways . 6-Demethoxytangeretin facilitates the CRE-mediated transcription associated with learning and memory in cultured hippocampal neurons .

HY-121619

Jacaric acid	Structural Classification Caprifoliaceae Ketones, Aldehydes, Acids Source classification Plants Centranthus ruber (L.) DC	Apoptosis
Jacaric acid is a conjugated linolenic acid, which inhibits viability in cells PC-3 (IC₅₀ is 11.8 μM), LNCaP (IC₅₀ is 2.2 μM) and DLD-1, induces apoptosis and necrosis . Jacaric acid exhibits anticaner activity against prostate cancer and adenocarcinoma . Jacaric acid exhibits immunomodulating activity in murine peritoneal macrophages as an immunopotentiator . Jacaric acid is orally active.

HY-W011303

Phytosphingosine 1 Publications Verification 4-Hydroxysphinganine	Infection Structural Classification Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Apoptosis Endogenous Metabolite Fungal Free Fatty Acid Receptor
Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC₅₀ value of 33.4 μM and can be used in the study of type II diabetes .

Species:	Human (12) Mouse (3)
Tag:	His (8) Tag Free (6) Strep (1) GST (1) B2M (1)
Source:	Sf9 insect cells (2) E. coli (13)

Cat. No.	Compare	Product Name	Species	Source

HY-P72102

	BCL6 Protein, Human (GST) B cell CLL/lymphoma 6; B cell lymphoma 6 protein; B-cell lymphoma 5 protein; B-cell lymphoma 6 protein; BCL 5; Bcl 6; BCL-5; BCL-6; BCL5; BCL6; BCL6_HUMAN; BCL6A; Protein LAZ-3; ZBTB 27; ZBTB27; Zinc finger protein 51; zinc finger transcription factor BCL6S; ZNF 51; ZNF51	Human	E. coli
	BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human (GST) is the recombinant human-derived BCL6 protein, expressed by E. coli , with N-GST labeled tag. The total length of BCL6 Protein, Human (GST) is 706 a.a., with molecular weight of ~105.5 kDa.

HY-P7537

	BCL2 Protein, Human (His) rHuApoptosis Regulator Bcl-2, His; B-cell lymphoma 2; Apoptosis Regulator Bcl-2	Human	E. coli
	BCL2 Protein, Human (His) expresses in E. coli with a His tag at the N-terminus. Proteins of the Bcl-2 family are important regulators of apoptosis in many tissues of the embryo and adult.

HY-P702575

	BCL6 Protein, Human B cell CLL/lymphoma 6; B cell lymphoma 6 protein; B-cell lymphoma 5 protein; B-cell lymphoma 6 protein; BCL 5; Bcl 6; BCL-5; BCL-6; BCL5; BCL6; BCL6_HUMAN; BCL6A; Protein LAZ-3; ZBTB 27; ZBTB27; Zinc finger protein 51; zinc finger transcription factor BCL6S; ZNF 51; ZNF51	Human	E. coli
	BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human is the recombinant human-derived BCL6 protein, expressed by E. coli , with tag free. The total length of BCL6 Protein, Human is 706 a.a., with molecular weight of 79.0 kDa.

HY-P702715

	ALK Protein, Human (L1196M, Biotinylated, sf9) ALK; anaplastic lymphoma receptor tyrosine kinase; anaplastic lymphoma kinase (Ki 1); ALK tyrosine kinase receptor; CD246; CD246 antigen; mutant anaplastic lymphoma kinase; NBLST3	Human	Sf9 insect cells

HY-P74530

	TCL1A Protein, Human (His) T-cell leukemia/lymphoma protein 1A; Oncogene TCL-1; TCL1A; TCL1	Human	E. coli
	TCL1A protein plays a crucial role in cell signaling by actively enhancing the phosphorylation and activation of AKT1, AKT2, and AKT3 while promoting the nuclear translocation of AKT1. Additionally, it aids cell proliferation, stabilizes mitochondrial membrane potential, and promotes cell survival. TCL1A Protein, Human (His) is the recombinant human-derived TCL1A protein, expressed by E. coli , with N-His labeled tag. The total length of TCL1A Protein, Human (His) is 113 a.a., with molecular weight of ~14 kDa.

HY-P701366

	CDK6-CCND1 Heterodimer Protein, Human (Sf9) CDK6; CCND1; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D1; B-cell lymphoma 1 protein; BCL-1; BCL-1 oncogene; PRAD1 oncogene	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND1 Heterodimer Protein, Human (Sf9) is a recombinant protein dimer complex containing human-derived CDK6-CCND1 Heterodimer protein, expressed by Sf9 insect cells , with tag free.

HY-P701951

	PARP14 Protein, Human PARP14; Protein mono-ADP-ribosyltransferase PARP14; ADP-ribosyltransferase diphtheria toxin-like 8; ARTD8; B aggressive lymphoma protein 2; Poly [ADP-ribose] polymerase 14; PARP-14	Human	E. coli
	The PARP14 protein is an ADP-ribosyltransferase that uniquely mono-ADP-ribosylates glutamic acid residues on target proteins such as STAT1 and STAT6, unlike PARP1 and PARP2. It catalyzes STAT1 mono-ADP ribosylation at “Glu-657” and “Glu-705”, reduces STAT1 phosphorylation and inhibits the production of pro-inflammatory cytokines in macrophages following IFNG stimulation. PARP14 Protein, Human is the recombinant human-derived PARP14 protein, expressed by E. coli , with tag free. The total length of PARP14 Protein, Human is 180 a.a., .

HY-P702072

	DTX3L Protein, Human DTX3L; E3 ubiquitin-protein ligase DTX3L; B-lymphoma- and BAL-associated protein; Protein deltex-3-like; RING-type E3 ubiquitin transferase DTX3L; Rhysin-2; Rhysin2	Human	E. coli
	DTX3L protein is an E3 ubiquitin protein ligase that cooperates with PARP9 in DNA damage repair and antiviral responses. It monoubiquitylates histones (H2A, H2B, H3, H4), especially “Lys-91” of H4, possibly signaling additional modifications. DTX3L Protein, Human is the recombinant human-derived DTX3L protein, expressed by E. coli , with tag free. The total length of DTX3L Protein, Human is 739 a.a., .

HY-P701952

	PARP14 Protein, Human (His, Strep) PARP14; Protein mono-ADP-ribosyltransferase PARP14; ADP-ribosyltransferase diphtheria toxin-like 8; ARTD8; B aggressive lymphoma protein 2; Poly [ADP-ribose] polymerase 14; PARP-14	Human	E. coli
	The PARP14 protein is an ADP-ribosyltransferase that uniquely mono-ADP-ribosylates glutamic acid residues on target proteins such as STAT1 and STAT6, unlike PARP1 and PARP2. It catalyzes STAT1 mono-ADP ribosylation at “Glu-657” and “Glu-705”, reduces STAT1 phosphorylation and inhibits the production of pro-inflammatory cytokines in macrophages following IFNG stimulation. PARP14 Protein, Human (His, Strep) is the recombinant human-derived PARP14 protein, expressed by E. coli , with N-Strep, N-8*His labeled tag. The total length of PARP14 Protein, Human (His, Strep) is 180 a.a., .

HY-P701953

	PARP15 Protein, Human (His) PARP15; Protein mono-ADP-ribosyltransferase PARP15; ADP-ribosyltransferase diphtheria toxin-like 7; ARTD7; B-aggressive lymphoma protein 3; Poly [ADP-ribose] polymerase 15; PARP-15	Human	E. coli
	PARP15 protein, acting as a mono-ADP-ribosyltransferase, facilitates the mono-ADP-ribosylation of target proteins. It also functions as a transcriptional negative regulator, impacting cellular processes and gene expression. PARP15 Protein, Human (His) is the recombinant human-derived PARP15 protein, expressed by E. coli , with N-6*His labeled tag. The total length of PARP15 Protein, Human (His) is 176 a.a., .

HY-P702073

	DTX3L Protein, Human (His) DTX3L; E3 ubiquitin-protein ligase DTX3L; B-lymphoma- and BAL-associated protein; Protein deltex-3-like; RING-type E3 ubiquitin transferase DTX3L; Rhysin-2; Rhysin2	Human	E. coli
	DTX3L protein is an E3 ubiquitin protein ligase that cooperates with PARP9 in DNA damage repair and antiviral responses. It monoubiquitylates histones (H2A, H2B, H3, H4), especially “Lys-91” of H4, possibly signaling additional modifications. DTX3L Protein, Human (His) is the recombinant human-derived DTX3L protein, expressed by E. coli , with N-6*His labeled tag. The total length of DTX3L Protein, Human (His) is 739 a.a., .

HY-P72220

	GZMA/Granzyme A Protein, Mouse (His-B2M) Gzma; Ctla-3; Ctla3; Mtsp-1; Granzyme A; EC 3.4.21.78; Autocrine thymic lymphoma granzyme-like serine protease; CTLA-3; Fragmentin-1; T cell-specific serine protease 1; TSP-1	Mouse	E. coli
	GZMA/Granzyme A, abundant in cytotoxic T-cells and natural killer cells, crucially induces caspase-independent pyroptosis upon delivery into target cells. With substrate specificity for lysine or arginine residues, GZMA cleaves APEX1 and nucleosome assembly protein SET, disrupting their activities. This multifunctional protein plays a significant role in diverse cellular processes during immune responses. GZMA/Granzyme A Protein, Mouse (His-B2M) is the recombinant mouse-derived GZMA/Granzyme A protein, expressed by E. coli, with N-6*His, N-B2M labeled tag. The total length of GZMA/Granzyme A Protein, Mouse (His-B2M) is 232 a.a., with molecular weight of ~39.6 kDa.

HY-P72119

	CCND1 Protein, Human (His) AI327039; B cell leukemia 1; B-cell lymphoma 1 protein; BCL 1; BCL-1; BCL-1 oncogene; BCL1; BCL1 oncogene; ccnd1; CCND1/FSTL3 fusion gene; CCND1/FSTL3 fusion gene; included; CCND1/IGHG1 fusion gene; CCND1/IGLC1 fusion gene; CCND1_HUMAN; cD1; Cyl 1; D11S287E; G1/S specific cyclin D1; G1/S-specific cyclin-D1; PRAD1; PRAD1 oncogene; U21B31	Human	E. coli
	The CCND1 protein is a regulatory component of the cyclin D1-CDK4 complex that coordinates phosphorylation and RB family inhibition to regulate the G(1)/S transition. This promotes the dissociation of E2F from the RB/E2F complex and promotes the transcription of E2F target genes critical for G(1) phase progression. CCND1 Protein, Human (His) is the recombinant human-derived CCND1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of CCND1 Protein, Human (His) is 295 a.a., with molecular weight of ~37.7 kDa.

HY-P70518

	SDF-1 alpha/CXCL12 Protein, Mouse (Tag free) Cxcl12; Stromal cell-derived factor 1; SDF-1; 12-O-tetradecanoylphorbol 13-acetate repressed protein 1; TPAR1; C-X-C motif chemokine 12; Pre-B cell growth-stimulating factor; PBSF; Thymic lymphoma cell-stimulating factor; TLSF; Sdf1	Mouse	E. coli
	CXCL12 (stromal cell-derived factor-1, SDF-1) is a homeostatic chemokine that binds CXCR4 and CXCR7 receptors and physiologically functions in hematopoiesis, leucocyte trafficking, cardiogenesis, and neurogenesis. CXCL12 is constitutively expressed in several organs including lung, liver, skeletal muscle, brain, kidney, heart, skin, and bone marrow. CXCL12 has an essential role in neural and vascular development, hematopoiesis, cancer and in immunity. CXCL12 Protein, Mouse is produced in E. coli, and consists of 68 amino acids (K22-K89).

HY-P700219AF

	Animal-Free SDF-1 alpha/CXCL12 Protein, Mouse (His) CXCL12; Stromal cell-derived factor 1; SDF-1; 12-O-tetradecanoylphorbol 13-acetate repressed protein 1; TPAR1; C-X-C motif chemokine 12; Pre-B cell growth-stimulating factor; PBSF; Thymic lymphoma cell-stimulating factor; TLSF; Sdf1	Mouse	E. coli
	The SDF-1 α/CXCL12 protein acts as a chemoattractant with specific activity on T lymphocytes and monocytes (excluding neutrophils). It activates the CXC chemokine receptor CXCR4, inducing a rapid and transient rise in intracellular calcium ions and promoting chemotaxis. Animal-Free SDF-1 alpha/CXCL12 Protein, Mouse (His) is the recombinant mouse-derived animal-FreeSDF-1 alpha/CXCL12 protein, expressed by E. coli , with C-His labeled tag. The total length of Animal-Free SDF-1 alpha/CXCL12 Protein, Mouse (His) is 69 a.a., with molecular weight of ~8.97 kDa.

Cat. No.	Product Name	Chemical Structure

HY-14171S

Bexarotene-d4
Bexarotene-d₄ is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].

HY-13582S

Carbendazim-d4

Carbendazim-d₄ is the deuterium labeled Carbendazim. Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria, Fusarium and Sclerotina[1][3]. Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma[3].

HY-129336S

Abemaciclib metabolite M20-d8
Abemaciclib metabolite M20-d₈ is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor[1].

HY-117433S

4-Hydroperoxy Cyclophosphamide-d4

4-Hydroperoxy Cyclophosphamide-d₄ is the deuterium labeled 4-Hydroperoxy cyclophosphamide. 4-Hydroperoxy cyclophosphamide is the active metabolite form of the proagent Cyclophosphamide. 4-Hydroperoxy cyclophosphamide crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS). 4-Hydroperoxy cyclophosphamide has the potential for lymphomas and autoimmune disorders[1][2].

HY-30151S

Methoxsalen-d3
Methoxsalen-d₃ is the deuterium labeled Methoxsalen[1]. Methoxsalen (8-Methoxypsoralen) is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight[2].

HY-N6703S

ar-Turmerone-d3

ar-Turmerone-d₃ is the deuterium labeled ar-Turmerone. ar-Turmerone ((+)-ar-Turmerone) is a major bioactive compound of the herb Curcuma longa with anti-tumorigenesis and anti-inflammatory activities[1][2][3]. ar-Turmerone activates apoptotic protein in human lymphoma U937 cells[3]. ar-Turmerone exerts positive modulation on murine DCs. ar-Turmerone induces NSC proliferation and constitutes a promising therapeutic agent for various neurologic disorders[4][5].

HY-A0003S

Lenalidomide-d5

Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

Cat. No.	Product Name	Application	Reactivity

HY-P81596

MALT1 Antibody (YA1341)

MALT1; MLT; Mucosa-associated lymphoid tissue lymphoma translocation protein 1; MALT lymphoma-associated translocation; Paracaspase
WB, ICC/IF, FC Human

HY-P81443

Bcl10 Antibody (YA1188) BCL10; CIPER; CLAP; B-cell lymphoma/leukemia 10; B-cell CLL/lymphoma 10; Bcl-10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; hCLAP; CED-3/ICH-1 prodomain homologous E10-like regulator; CIPER; Cellular homolog	IHC-P	Human

HY-P81536

Bcl6 Antibody (YA1281) BCL6; BCL5; LAZ3; ZBTB27; ZNF51; B-cell lymphoma 6 protein; BCL-6; B-cell lymphoma 5 protein; BCL-5; Protein LAZ-3; Zinc finger and BTB domain-containing protein 27; Zinc finger protein 51	IHC-P	Human

HY-P81959

T Cell Leukemia/Lymphoma Protein 1A Antibody (YA1704)

Anti TCL1A; P14 TCL1; T cell leukemia 1; TCL1; TCL1 PEN; Tcl1a
WB, IHC-P, ICC/IF, FC Human

HY-P82647

CBL Antibody (YA2392) CBL; CBL2; RNF55; E3 ubiquitin-protein ligase CBL; Casitas B-lineage lymphoma proto-oncogene; Proto-oncogene c-Cbl; RING finger protein 55; Signal transduction protein CBL	WB, ICC/IF, IP	Human

HY-P81294

Phospho-CBL (Tyr774) Antibody (YA1014) CBL; CBL2; RNF55; E3 ubiquitin-protein ligase CBL; Casitas B-lineage lymphoma proto-oncogene; Proto-oncogene c-Cbl; RING finger protein 55; Signal transduction protein CBL	WB, IP	Human, Rat

HY-P81294A

Phospho-CBL (Ser669) Antibody (YA1015) CBL; CBL2; RNF55; E3 ubiquitin-protein ligase CBL; Casitas B-lineage lymphoma proto-oncogene; Proto-oncogene c-Cbl; RING finger protein 55; Signal transduction protein CBL	WB	Human

HY-P82361

CXCR5 Antibody (YA2106) CXCR5; BLR1; MDR15; C-X-C chemokine receptor type 5; CXC-R5; CXCR-5; Burkitt lymphoma receptor 1; Monocyte-derived receptor 15; MDR-15; CD185	WB, ICC/IF, FC	Human, Mouse, Rat

Cat. No.	Product Name		Classification

HY-10446

Pralatrexate 4 Publications Verification		Alkynes
Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a K_i of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment . Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-161080

4'-Ethynyl-2'-deoxycytidine		Alkynes
4'-Ethynyl-2'-deoxycytidine is an anticancer nucleoside. 4'-Ethynyl-2'-deoxycytidine can used in study acute lymphoblastic leukemia and diffuse large B-cell lymphoma .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry